[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital of Harbin Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":257},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,73,98,123,144,168,193,219,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634519","efficacy-and-safety-of-pcsk9-inhibitors-in-patients-with-large-artery-atherosclerosis-laa-ischemic-stroke-100634519",false,"NCT07540741","Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke","Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke: A Prospective Multicenter Cohort Study","Inclusion Criteria:\n\n1. Age 18-80 years.\n2. Acute ischemic stroke diagnosed according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke (2023), based on clinical and imaging criteria.\n3. Large-artery atherosclerotic subtype (TOAST classification) confirmed within 72 hours after stroke onset.\n4. NIHSS score 4-20 before treatment.\n5. Pre-stroke modified Rankin Scale (mRS) score ≤1.\n6. LDL-C ≥1.8 mmol\u002FL before enrollment.\n7. Able to use evolocumab and statin medications in accordance with the physician's instructions and the prescribing information.\n8. No prior use of a PCSK9 inhibitor before enrollment.\n9. Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Hemorrhagic transformation or other intracranial hemorrhage (including hemorrhagic infarction, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma), except cerebral microbleeds detected only by SWI.\n2. Prior intracranial or extracranial endovascular therapy before enrollment, planned acute endovascular therapy within 90 days, or planned surgery that may affect outcome assessment.\n3. Severe cardiac insufficiency：NYHA class III or IV.\n4. Severe hepatic dysfunction (ALT or AST \\>3 x upper limit of normal) or severe renal dysfunction (serum creatinine \\>2 mg\u002FdL, eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2, or requiring dialysis).\n5. Platelet count \\\u003C100 x 10\\^9\u002FL.\n6. Pregnancy or breastfeeding.\n7. Participation in another interventional clinical study within 30 days before enrollment, or concurrent participation in another interventional study that may affect outcome assessment.\n8. Giant intracranial tumor, giant cerebral aneurysm, or arteriovenous malformation.\n9. Active gastrointestinal ulcer, active bleeding tendency: corrected international normalized ratio (INR) \\> 1.5, bleeding time exceeding the upper limit by more than 1 minute, or increased bleeding risk due to heparin-induced thrombocytopenia; major systemic bleeding occurring within 30 days prior to enrollment.\n10. Pre-existing neurologic or psychiatric disease likely to affect neurologic or functional outcome assessment; severe neurologic deficit causing loss of independent living; dementia or psychiatric disease preventing completion of follow-up.\n11. Autoimmune disease (for example systemic sclerosis, systemic lupus erythematosus, Sjogren syndrome, Behcet disease, mixed connective tissue disease, or IgG4-related disease).\n12. Active seizures, hypotension, hyperthyroidism, asthma, and other allergic respiratory diseases, as well as individuals with a tendency toward allergies.\n13. Any other condition judged by the investigator to make participation inappropriate or to pose substantial risk.","ALL","18 Years","80 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","This prospective multicenter cohort study aims to evaluate the effectiveness and safety of early PCSK9 inhibitor therapy in patients with large-artery atherosclerotic ischemic stroke. The study will compare early neurological improvement, lipid-lowering effect, 90-day functional outcome, recurrent cardio-cerebrovascular events, and safety outcomes between patients treated with evolocumab plus statin and those treated with statin alone.",[25],"Acute Ischemic Stroke",[27,28,29,30],"PCSK9 inhibitor","Cohort study","Large-Artery Atherosclerotic","Functional outcome","RECRUITING","2026-04-19",{"date":34,"type":35},"2026-04-23","ACTUAL",{"date":37,"type":35},"2025-12-03",{"date":39,"type":21},"2027-12-01",{"name":41,"class":42},"First Affiliated Hospital of Harbin Medical University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100599638","effects-of-ketone-esters-on-circulating-senescent-t-lymphocytes-t-cells-and-inflammation-levels-in-the-elderly-100599638","NCT07087093","Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly","Inclusion Criteria:\n\n1. Age: 65\\~80 years old.\n2. The subjects are in good health, and no history of chronic diseases.\n\nExclusion Criteria:\n\n1. Have used immunosuppressants or hormone drugs in the past six months.\n2. There has been a significant change in diet within the past month.\n3. Having digestive tract surgery within one year.\n4. Severe liver dysfunction (alanine aminotransferase level \\> 3.0 upper limit of normal).\n5. Severe kidney dysfunction (creatinine clearance rate \\\u003C 30 mL\u002Fmin).\n6. History of malignant tumor.",true,"65 Years",{"count":53,"type":21},20,"INTERVENTIONAL",[56],"NA","Studies have shown that aging can promote a variety of pathological processes, such as myocardial remodeling and cardiac dysfunction caused by ischemia-reperfusion injury and pressure load. Previous studies found that the level of circulating beta-hydroxybutyric acid decreased significantly with age. It has been reported that the ketogenic diet reduces the occurrence of tumors and neurodegenerative diseases in mice, improves motor coordination and endurance, and ultimately extends life span. Current research results have confirmed that ketone bodies have multiple mechanisms to exert beneficial effects on cardiovascular diseases. However, the effect of age-related cardiovascular disease has not been reported.\n\nIn order to further clarify the role of beta-hydroxybutyric acid in age-related cardiovascular diseases, find new intervention targets for elderly cardiovascular diseases, and develop new effective prevention and treatment measures for elderly cardiovascular diseases. We will further investigate this hypothesis by establishing a clinical cohort of the elderly population.",[59],"The Elderly",[61,62,63,64],"ketone ester","the eldly","Senescent T cell","inflammatory factors","2025-07-23",{"date":67,"type":35},"2025-07-25",{"date":69,"type":35},"2025-01-07",{"date":71,"type":21},"2025-12-30",{"name":41,"class":42},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100594496","qfr-based-functional-syntax-score-system-in-optimizing-revascularization-strategy-for-multivessel-disease-100594496","NCT07020195","QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease","QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease: A Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Diagnosed as MVD patient by coronary angiography (≥ 50% stenosis in ≥ 2 major vessels);\n* Plan to undergo PCI or CABG treatment, and ensure that the contrast images meet the imaging quality requirements for QFR analysis;\n* Voluntarily sign the informed consent form, be able to participate in randomization and cooperate in completing all follow-up visits.\n\nExclusion Criteria:\n\n* Acute myocardial infarction requires emergency PCI;\n* Severe left ventricular dysfunction (LVEF\\\u003C30%) or cardiogenic shock;\n* The quality of coronary angiography images is poor, such as vascular overlap, respiratory artifacts, projection angles less than 25 °, or frame rates less than 15 frames per second;\n* Failure of QFR analysis due to severe calcified lesions (determined by the central laboratory);\n* eGFR\\\u003C30 mL\u002Fmin\u002F1.73m ² or contrast agent allergy;\n* Patients using intravenous pressors, intra aortic balloon counterpulsation, or other mechanical circulatory support devices;\n* Patients undergoing tracheal intubation treatment;\n* Patients who have received thrombolytic therapy before admission;\n* Pregnant women;\n* Expected survival time\\\u003C1 year due to non cardiac reasons;\n* Patients who are not expected to receive antiplatelet therapy for at least 6 months;\n* Patients who have received CABG treatment in the past or plan to receive CABG treatment;\n* Patients who plan to undergo any surgical procedure within 6 months;\n* There are other conditions that may interfere with follow-up, such as dementia, drug abuse including drug use and drug dependence for other reasons.",{"count":81,"type":21},1200,[56],"The revascularization treatment of multi vessel coronary artery disease (MVD) has always been a complex and important field in the treatment of coronary heart disease. The relative benefits of PCI and CABG vascular reconstruction strategies have always been a controversial topic in the field of MVD treatment. At present, SYNTAX score is the most commonly used imaging scoring system in clinical practice for quantitatively evaluating the complexity of coronary artery MVD, preliminary selection of revascularization strategies, and risk stratification. However, the SYNTAX score is entirely based on anatomical information of the lesion, and the assessment of the degree of coronary artery ischemia caused by the lesion is not accurate enough. Relying solely on anatomical structures for scoring may overestimate the harm of non ischemic lesions. The functional SYNTAX score (FSS) combines functional assessment of coronary artery lesions with anatomical structure scoring, only including lesions with hemodynamic significance, effectively optimizing the traditional SYNTAX scoring system. Compared with traditional SYNTAX scoring, FSS can reduce the number of high-risk patients, objectively evaluate the functional significance of lesions, and guide PCI treatment, significantly improving clinical prognosis.\n\nQuantitative flow ratio (QFR) is a novel method for evaluating the functional significance of coronary artery stenosis. However, it is currently unclear whether FSS based on QFR can achieve objective and accurate risk stratification, guide the selection of revascularization strategies, and improve the long-term prognosis of patients with coronary artery MVD. Higher quality prospective clinical trials need to be designed for verification.\n\nTherefore, this study will use a functional SYNTAX scoring system based on QFR (QFR-FSS) to conduct a prospective, multicenter, randomized controlled clinical trial to evaluate the guiding value of QFR-FSS in selecting revascularization strategies for patients with coronary artery MVD and its impact on long-term cardiovascular prognosis.",[85],"Cardiovascular Diseases",[87,88],"Multivessel Disease","QFR-Based Functional SYNTAX Score System","NOT_YET_RECRUITING","2025-06-05",{"date":92,"type":35},"2025-06-13",{"date":94,"type":21},"2026-01-01",{"date":96,"type":21},"2029-12-31",{"name":41,"class":42},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":50,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100592594","multivariate-analysis-and-prediction-of-hypertensive-disorder-complicating-pregnancy-and-its-related-mechanism-100592594","NCT06995456","Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism","Inclusion Criteria:\n\n1. singleton pregnancy;\n2. Those who meet the relevant diagnostic criteria in Guidelines for the Diagnosis and Treatment of Hypertensive Disorders during Pregnancy (2020).\n\nExclusion Criteria:\n\n1. Patients with severe cardiovascular diseases, blood system diseases and organ damage before pregnancy;\n2. Persons with severe mental illness;\n3. Pregnant women who gave birth to children with birth defects in pregnancy outcome;\n4. Patients who are not suitable for taking blood samples, such as anemia;\n5. Patients who are in an emergency during operation and are difficult to take tissue samples;\n6. Patients with chronic hypertension complicated with pregnancy;\n7. History of taking antibiotics, immunotoxic drugs, hormone antagonists and large doses of probiotics within 3 months;\n8. Patients who refused to participate in the trial.","FEMALE","20 Years","45 Years",{"count":108,"type":21},400,"Hypertensive disorder complicating pregnancy (HDP) is a unique disease during pregnancy, accounting for about 5.2% \\~ 8.2% of pregnant women in the world, which seriously threatens the health and life safety of mothers and infants, and is also one of the important causes of maternal and perinatal deaths. At present, the pathogenesis of HDP is not completely clear, and there is a lack of early effective early warning molecules and limited treatment methods. It is of great significance to find biomarkers that can predict the occurrence of HDP in early pregnancy and explore the pathogenesis of HDP in depth. Intestinal flora is a complex and huge microbial community existing in the digestive tract, which has the function of independent metabolism and plays a vital role in maintaining the dynamic balance of the body and promoting the occurrence and development of diseases. It is found that the intestinal flora and metabolites of pregnant women with HDP have changed significantly, and they are related to blood pressure and proteinuria. Supplementing intestinal microbial decomposition products (such as butyrate, propionate, etc.) in HDP rats can improve intestinal barrier function, inhibit inflammatory reaction, and then lower blood pressure. Therefore, the imbalance of intestinal flora and its metabolites can lead to intestinal barrier damage and activate inflammatory reaction, which may be an important cause of HDP. The investigators selected the patients who underwent prenatal examination and delivery in the First Affiliated Hospital of Harbin Medical University from July 2024 to July 2027, and divided them into control group and hypertensive disorder complicating pregnancy group, with 200 cases in each group. Samples of peripheral blood, feces, placenta, umbilical cord and umbilical cord blood of pregnant women with different gestational weeks were collected, and 16S r DNA sequencing was used to find out the differentially expressed pathogenic strains. At the same time, the metabonomics of feces and plasma samples were detected, combined with clinical data analysis, to find out the molecular markers that can predict the occurrence of hypertensive disorder complicating pregnancy, and to find out the potential preventive measures and therapeutic targets.",[111],"Hypertensive Disorder Complicating Pregnancy",[113,114],"HDP","gut microbiota","2025-05-26",{"date":117,"type":35},"2025-05-29",{"date":119,"type":21},"2025-05-25",{"date":121,"type":21},"2028-05-25",{"name":41,"class":42},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":50,"sex":16,"minAge":4,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":143,"locationsCount":43},"100591066","study-on-the-mechanism-of-multi-group-analysis-of-the-influence-of-depression-on-common-cardiovascular-diseases-100591066","NCT06975592","Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases","Inclusion Criteria:\n\n1. Healthy control group 1) Good health and no gastrointestinal diseases; 2) No previous history of mental illness; 3) No previous history of cardiovascular disease;\n2. Depression group\n\n1\\) Meet the diagnostic criteria of the latest guidelines for depression, and be clinically diagnosed by at least two psychiatrists; 2) Patients with first-episode depression; 3) Have not taken any psychoactive drugs before or have not taken any psychoactive drugs within 4 weeks.\n\n3\\. Depression with cardiovascular disease group\n\n1. Meet the diagnostic criteria of the latest guidelines for depression, and be clinically diagnosed by at least two psychiatrists;\n2. Patients with first-episode depression;\n3. Have not taken any psychoactive drugs before or have not taken any psychoactive drugs within 4 weeks.\n4. There is definite clinical evidence of heart failure, coronary heart disease, hypertension or arrhythmia.\n\nExclusion Criteria:\n\n1. Have a history of alcohol dependence, organic brain diseases, nervous system diseases and other complex mental diseases;\n2. Long-term use of psychoactive drugs\u002Fuse of psychoactive drugs within 4 weeks;\n3. Patients with thyroid dysfunction\n4. Patients with severe liver and kidney dysfunction;\n5. Patients with chronic obstructive pulmonary disease, interstitial pulmonary fibrosis and pulmonary hypertension;\n6. Patients with autoimmune diseases and tumors;\n7. used antibiotics, yogurt or other drugs or foods that affect intestinal flora within 4 weeks;\n8. Pregnant or lactating women;\n9. There is a serious impairment of cognitive function, which makes it impossible to cooperate with the research procedure;\n10. Have received invasive medical procedures such as gastroscopy and colonoscopy in the past three months;\n11. The diet has changed greatly in the past week;\n12. Participate in simultaneous clinical trials;\n13. Refuse to sign the informed consent for participating in the experiment.","85 Years",{"count":131,"type":21},300,"Cardiovascular disease is the main cause of death in the world, accounting for 32% of all deaths. In 2019, the number of people suffering from cardiovascular diseases in the world was about 523 million, of which about 18.6 million died of cardiovascular diseases. Although great progress has been made in reducing the burden of cardiovascular diseases by controlling typical risk factors, there is still a lack of effective intervention means and measures for cardiovascular diseases induced by atypical risk factors (such as environmental pollution, obesity and anxiety and depression).\n\nDepression is a health problem as common as cardiovascular disease, and it has been proved to be an important risk factor of cardiovascular disease. Previous studies have shown that depression is related to the increased risk of subsequent cardiovascular events, including myocardial infarction, angina pectoris, stroke and cardiovascular mortality. The risk of cardiovascular disease in patients with major depression is about 72% higher than that in healthy control group.\n\nPrevious studies have shown that compared with healthy people, the intestinal microbial composition of patients with major depression, especially the microbial diversity and the relative abundance of specific bacterial groups, has changed significantly. Many studies have also confirmed that dysbacteriosis may be an important cause of MDD, and with the passage of time, the pathological changes caused by MDD will further destroy the intestinal environment and lead to dysbacteriosis. In addition, intestinal microflora can also produce a variety of important mediators, such as metabolites produced by bacterial fermentation of food, host molecules modified by bacteria (bile acids, etc.) or direct products of bacteria, which also play an important role in the pathogenesis of MDD. In recent years, both population studies and animal experiments have found that the changes in the composition and function of intestinal flora (that is, the imbalance of intestinal microbial flora) will accelerate the occurrence and development of cardiovascular diseases. Intestinal flora will metabolize the food ingested by the host into a series of metabolites, including trimethylamine oxide, short-chain fatty acids, secondary bile acids and indole sulfate, etc. These metabolites will affect the physiological process of the host by activating various signal pathways, thus affecting the occurrence and development of cardiovascular diseases (such as coronary heart disease, hypertension, arrhythmia and heart failure).\n\nAll the above results suggest that intestinal flora and its metabolites play an important role in promoting the occurrence and development of cardiovascular diseases in depression, but its internal mechanism is not completely clear. Therefore, it is of great significance to deeply explore the pathophysiological mechanism of depression on cardiovascular diseases for guiding the prevention and treatment of cardiovascular diseases.\n\nA total of 300 people were enrolled in this study, which were divided into healthy control group, depression group and depression combined with cardiovascular disease group, with 100 cases in each group. Samples of patients' feces, urine peripheral blood and oral secretions were collected and analyzed by multi-omics. Subsequently, after 6 months, 1 year, 2 years and 5 years after discharge, the clinical prognosis of the patients was obtained and recorded.\n\nThe purpose of this study is to discover and deeply explore the pathophysiological mechanism of depression on common cardiovascular diseases (coronary heart disease, hypertension, arrhythmia or heart failure) through the research methods of 16S rDNA sequencing, metagenome sequencing and metabonomics, so as to provide theoretical basis for comprehensive treatment of cardiovascular diseases caused by depression, and at the same time provide potential biomarkers and prevention targets for cardiovascular diseases caused by depression.",[134],"Depression and CVD",[136],"Depression and cardiovascular diseases","2025-05-08",{"date":139,"type":35},"2025-05-16",{"date":119,"type":21},{"date":142,"type":21},"2029-07-01",{"name":41,"class":42},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":43},"100568350","study-on-lipid-profile-changes-in-plasma-and-intestinal-mucosa-of-patients-with-inflammatory-bowel-disease-100568350","NCT06680076","Study on Lipid Profile Changes in Plasma and Intestinal Mucosa of Patients With Inflammatory Bowel Disease","Observational Study of Changes in Plasma and Intestinal Mucosa Lipid Profiles in Patients With Inflammatory Bowel Disease","Inclusion Criteria:\n\n* Patients with inflammatory bowel disease; aged 18-80 years; all cases agreed to participate in the study.\n* Healthy volunteers who agreed to participate in the study.\n\nExclusion Criteria:\n\n* Patients with severe heart disease; patients with severe kidney disease; patients with low blood pressure; patients with severe infections such as sepsis or pneumonia; patients who have used immunosuppressants such as 6-mercaptopurine, imidazole thiopurine, and cyclosporine within a short period, and women during pregnancy; patients who are post-colon resected; patients who disagreed to participate in the study.",{"count":152,"type":21},90,"This study aimed to demonstrate the characteristic lipid profile changes in patients with inflammatory bowel disease.",[155],"Inflammatory Bowel Diseases",[157,158,159],"IBD","lipid metabolism","activity","2024-12-10",{"date":162,"type":35},"2024-12-12",{"date":164,"type":21},"2024-12",{"date":166,"type":21},"2025-03-30",{"name":41,"class":42},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":54,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":43},"100569627","effect-of-human-urinary-kallidinogenase-on-inflammatory-factors-in-acute-ischemic-stroke-kif-ais-100569627","NCT06696703","Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)","Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke: a Single-center, Randomized, Open Label, Blinded-endpoint, Controlled Study(KIF-AIS)","Inclusion Criteria:\n\n1. Diagnosis as acute ischemic stroke according to the Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018;\n2. First clinical onset or previous presence of cerebral infarction without severe sequelae（Premorbid mRS ≤2）\n3. Age≥18 years, male or female;\n4. 3≤Baseline NIHSS≤25;\n5. Written informed consent obtained from the patient or legally responsible person.\n\nExclusion Criteria:\n\n1. Cerebral hemorrhage and the acute phase of other hemorrhagic diseases；\n2. Previously allergic or intolerant to injectable HUK；\n3. Used ACEI drugs prior to medication and less than 5 half-lives of the drug (according to the specific drug instructions) or received ACEI drugs during the study period;\n4. Stent surgery after the AIS onset or planned interventional therapy;\n5. Pregnancy, lactation or planned pregnancy；\n6. Life expectancy of less than 3months or inability to complete the study for other reasons；\n7. Unwilling to be followed up or poor compliance；\n8. Current participation in other clinical research;\n9. Other causes of AIS (such as dissection, vasculitis, pre-thrombotic lesions, drug abuse).",{"count":176,"type":21},200,[56],"The goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of Human Urinary Kallidinogen (HUK) in the acute ischemic stroke. It will also learn about the correlation between inflammatory factors and AIS prognosis, in order to clarify the efficacy and safety of Urinary Kallidinogen in the acute phase of AIS.",[25],[181,182,183,184],"Acute ischemic stroke","Urinary Kallidinogen","Inflammatory factors","90 days functional outcomes","2024-11-19",{"date":187,"type":35},"2024-11-20",{"date":189,"type":35},"2024-01-01",{"date":191,"type":21},"2025-12-01",{"name":41,"class":42},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":104,"minAge":200,"maxAge":51,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":43},"100559570","analysis-of-various-treatment-methods-of-granulomatous-lobular-mastitis-100559570","NCT06565845","Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis","Analysis of the Clinical Characteristics and Three Treatment Methods of Granulomatous Lobular Mastitis","Inclusion Criteria:\n\n* non-lactating and aged 15-65 years\n* histopathological confirmation of GLM\n* normal liver and kidney function\n\nExclusion Criteria:\n\n* lactating and pregnant women\n* allergies to rifampin, isoniazid, or ethambutol\n* concurrent malignant breast tumors\n* severe underlying diseases\n* other conditions deemed unsuitable by the investigator and\n* refusal to participate in the study","15 Years",{"count":202,"type":21},350,"Granulomatous lobular mastitis (GLM) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment. This study aims to analyze the clinical characteristics and demographic data of GLM patients and to compare the overall effectiveness of three treatment methods: surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy, with the goal of providing new insights for clinical treatment.",[205],"Granulomatous Mastitis",[207,208,209,210],"Granulomatous lobular mastitis","surgical treatment","antituberculosis therapy","surgery combined with anti-tuberculosis therapy","2024-08-21",{"date":213,"type":35},"2024-08-22",{"date":215,"type":35},"2024-08-19",{"date":217,"type":21},"2024-10-19",{"name":41,"class":42},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":225,"maxAge":18,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":43},"100542422","study-on-the-expression-level-and-clinical-significance-of-vista-in-patients-with-vascular-cognitive-impairment-100542422","NCT06342661","Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment","Inclusion Criteria:\n\n1. The study included 100 subjects, including 50 patients with VCI and 50 normal controls. The diagnosis of VCI was based on the diagnostic criteria for psychiatric disorders in the fifth revised edition of the \"Diagnostic and Statistical Manual of Mental Disorders\" of the American Psychiatric Association;\n2. All relevant examination and cognitive testing work in this study obtained informed consent from the subjects and their families.\n\nExclusion Criteria:\n\n1\\. In line with the exclusion criteria for VCI diagnosis in the \"Chinese guidelines for the treatment of vascular cognitive impairment 2019\"; complicated with autoimmune diseases, blood diseases, malignant tumors, heart, liver, and kidney dysfunction, infectious diseases, family genetic diseases, recent acute or chronic inflammatory diseases, myocardial infarction, etc.; taking antibiotics, steroids, immunosuppressants before the trial; having a history of cranial trauma or surgery.","50 Years",{"count":108,"type":21},"1\\. Explore the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors; 2. Discuss the correlation between different risk factors (mainly hypertension, diabetes, smoking, hyperlipidemia, hyperhomocysteinemia, etc.) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cerebrovascular diseases and immune-inflammatory related diseases of the nervous system; 3. Explore the correlation between different immune inflammatory factors (IL1, IL6, IL10, INFγ, TNFα) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients; 4. Track and explore the dynamic changes of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors in 3 months, 1 year, 3 years, and 5 years.",[229],"Cerebrovascular Disease Small Vessel","2024-03-26",{"date":232,"type":35},"2024-04-02",{"date":234,"type":35},"2023-03-01",{"date":236,"type":21},"2028-11",{"name":41,"class":42},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":43},"100323695","a-prospective-study-of-low-dose-decitabine-combined-with-cop-regimen-in-the-treatment-of-relapsed-and-refractory-dlbcl-100323695","NCT03494296","A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL","Inclusion Criteria:\n\n1. Histopathology confirmed as DLBCL.\n2. Relapsed and refractory patients.\n3. Age ≥ 18 years old.\n4. ECOG ≥ 3.\n5. Women are not lactating, not pregnant, and agree not to become pregnant during the study period and within the next 12 months. Male patients agree that their spouse is not pregnant during the study period and within the next 12 months。\n6. There is an assessable lesion (lymph node diameter ≥ 1.0cm; or a dermatologic lesion that can be assessed by a physical examination)Signed informed consent\n\nExclusion Criteria:\n\n1. Bone marrow involvement and lymphoma cells ≥ 25%.\n2. Severe abnormal liver and kidney function (alanine aminotransferase, bilirubin, creatinine\\> 3 times the upper limit of normal).\n3. Uncontrolled active infections.\n4. Organic heart disease and clinical symptoms or abnormal heart function (NYHA ≥ 2).\n5. Simultaneous presence of other tumors.\n6. Other psychological conditions that prevent patients from participating in the study or signing informed consent",{"count":245,"type":21},150,"Decitabine is a cytosine analogue and is a specific DNA methyltransferase (DNMT) inhibitor. It directly inhibits DNMT by phosphorylating DNA and inhibits DNMT, thereby reversing DNA methylation and inducing tumor cells to Normal cell differentiation or induction of tumor cell apoptosis.Diffuse large B-cell lymphoma (DLBCL) is the most common pathological type in non-Hodgkin's lymphoma. The first-line chemotherapy regimen using Rituximab+Cyclophosphamide+Doxorubicin +Vincristine+Bonisone（R-CHOP）significantly increases the remission rate and disease-free survival of patients with DLBCL, but it is difficult to partially relapse. Long-term remission and survival rates in treating patients are not satisfactory.Due to the greater cardiac toxicity of adriamycin, more patients can not be uncomfortable, so the COP program is also widely used in patients with DLBCL, and achieved a good response rate.In 2008, the FDA had approved decitabine for the demethylation treatment of Myelodysplastic syndrome（MDS）. Over the years, good initial remission rates and better long-term survival rates have been achieved in patients with MDS.There are also a variety of clinical trials of decitabine for patients with solid tumors that have achieved significant clinical efficacy.Due to the high side effects of high-dose decitabine, patient tolerance is poor. Therefore, the purpose of this study was to evaluate the efficacy and safety of low-dose decitabine combined with Cyclophosphamide+Vindesine+Bonisone(COP) regimen (D-COP) 4-6 course of treatment for relapsed and refractory diffuse large B-cell lymphoma.",[248],"Lymphoma","2018-04-10",{"date":251,"type":35},"2018-04-11",{"date":253,"type":35},"2018-03-01",{"date":255,"type":21},"2026-12-31",{"name":41,"class":42},""]